Evidence map›Paper›PMID 10764846›Full record

ReviewThe American journal of medicine2000

Combining sulfonylureas and other oral agents.

M Riddle

Registry-linked trialAbstract readReview
PubMed Publisher
In one paragraph

Review in The American journal of medicine, 2000. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00941161 (Effect of Oral Combination Therapy of Metformin Extended Release Over Glimepiride in a Single Dosage Form in Patients With Type 2 Diabetes Mellitus With Failure of Monotherapy), which is not on this map. Cited by 25 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed, 3 pooled it
3.6field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00941161 phase4completedstarted 2009, after this paper: background citation

Effect of Oral Combination Therapy of Metformin Extended Release Over Glimepiride in a Single Dosage Form in Patients With Type 2 Diabetes Mellitus With Failure of Monotherapy

Ran2009Enrolled28Registered outcomes2Posted comparisons0ConditionsType 2 Diabetes MellitusArmsGlimepiride, Metformin, metformin/glimepiride combination
PMID 15612515PMID 16567811PMID 8569826PMID 17414590PMID 17065711PMID 16802130PMID 10520820PMID 11336617PMID 16751851PMID 8911975PMID 17666882other papers from this trial
Open the trial in the graph
3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 3 syntheses or guidelines pooled it, 135 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Trial
  6. Trial
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Personal features and dropout from diabetic care.Environmental health and preventive medicine · 2006
    Article
  13. Review
  14. Article
  15. Insulin secretagogues: who, what, when, and how?Current diabetes reports · 2005
    Review
  16. Review
  17. Article
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

M RiddleDivision of Endocrinology, Diabetes, and Clinical Nutrition, Oregon Health Sciences University, Portland, Oregon 97201, USA. riddlem@ohsu.edu
Oregon Health & Science University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Type 2 diabetes mellitus is a progressive disorder, and although oral monotherapy is often initially successful, it is associated with a high secondary failure rate, which contributes to the development of long-term diabetes complications resulting from persistent hyperglycemia. For patients not taking insulin, accumulating evidence suggests that combination therapy using oral antidiabetic agents with different mechanisms of action may be highly effective in achieving and maintaining target blood glucose levels. Low-dose combination therapy may be associated with fewer side effects than higher-dose monotherapy and may achieve similar or better glycemic control. The best-studied combination is that of sulfonylurea compounds plus metformin, a therapeutic approach that addresses both underlying defects in the disorder: insulin deficiency and insulin resistance. Other multidrug regimens under investigation are sulfonylurea compounds plus either alpha-glucosidase inhibitors or thiazolidinediones, and combinations of various insulin-sensitizing agents. For many patients, combination oral therapy may be used appropriately as primary management early in the course of type 2 diabetes, along with diet modification and exercise. Later in the course of the disease, the use of combinations of oral agents may delay the need for insulin while maintaining glycemic control, thus making aggressive oral treatment more acceptable for many patients.

Indexed as

AcarboseAdministration, OralCarbamatesDiabetes Mellitus, Type 2Dose-Response Relationship, DrugDrug Therapy, CombinationGlyburideHumansHypoglycemic AgentsMetforminPiperidinesSulfonylurea CompoundsAcarboseCarbamatesglimepirideGlyburideHypoglycemic AgentsMetforminPiperidinesrepaglinideSulfonylurea Compounds

Identifiers

PMID10764846
OpenAlexW2023549874

What OpenQuestion holds

Texttitle and abstract
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.